EMEA-002608-PIP01-19

Key facts

Active substance
2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid
Therapeutic area
Oncology
Decision number
P/0357/2019
PIP number
EMEA-002608-PIP01-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Diagnosis of prostate cancer
Route(s) of administration
Intravenous use
Contact for public enquiries
Curium Netherlands B.V.

E-mail: regulatory.cyclopharma@curiumpharma.com
Tel. +33 473632713

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating